ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Manisha Singh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9345-8472; OpenAlex author ID A5041573971. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2026: 1 paper

Papers 1

IL1R1 blockade augments CD40 agonist mediated immunity in pancreatic cancer. Last author DOI 10.1038/s41598-026-42259-8 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Akash R. Boda · 1 shared paper, 2026 · strength 0.27
- Paper IL1R1 blockade augments CD40 agonist mediated immunity in pancreatic cancer. DOI 10.1038/s41598-026-42259-8 ↗
Saikat Chowdhury · 1 shared paper, 2026 · strength 0.27
- Paper IL1R1 blockade augments CD40 agonist mediated immunity in pancreatic cancer. DOI 10.1038/s41598-026-42259-8 ↗
Jason Roszik · 1 shared paper, 2026 · strength 0.27
- Paper IL1R1 blockade augments CD40 agonist mediated immunity in pancreatic cancer. DOI 10.1038/s41598-026-42259-8 ↗
Scott Kopetz · 1 shared paper, 2026 · strength 0.27
- Paper IL1R1 blockade augments CD40 agonist mediated immunity in pancreatic cancer. DOI 10.1038/s41598-026-42259-8 ↗
Michael A. Curran · 1 shared paper, 2026 · strength 0.27
- Paper IL1R1 blockade augments CD40 agonist mediated immunity in pancreatic cancer. DOI 10.1038/s41598-026-42259-8 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.